Samuel Wu, MD, PhD, Chair
Sam has been a healthcare venture capital investor since 2002. He is a founding partner at Acuris, which was recently launched by the MedImmune Ventures team out of AstraZeneca. Previously he was the managing director of MedImmune Ventures’ West Coast office from 2010 to 2016, and a principal at SV Life Sciences, where he invested in a broad range of biopharmaceutical, platform and medical device companies. Sam is or has been a board member of Applied Genetic Technologies Corp (NASDAQ:AGTC), Cerapedics, Hydra Biosciences, Ocular Therapeutix (NASDAQ:OCUL), and the California Life Sciences Institute. Prior to his VC career, he was an Engagement Manager with McKinsey and Company, leading teams of consultants serving life science clients on M&A, portfolio analysis and other strategic issues.
Sam holds a B.A. magna cum laude in Biochemistry from Harvard University, attended Stanford University School of Medicine where he earned an M.D. and a Ph.D. in Biochemistry as a Howard Hughes Fellow, and trained in Internal Medicine at the University of California, Los Angeles.